2025 Q4 -tulosraportti
Vain PDF
45 päivää sitten
6,2762 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 17.2. | ||
2025 Q3 -tulosraportti 11.11.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 13.5.2025 | ||
2024 Q4 -tulosraportti 11.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·30.3.The company's communication to shareholders is deplorable. A company in this situation that communicates 1 time per quarter... and not very much even then. And their page on Linkedin (which after all many look up and they have 2000+ followers) where the About section was updated 2022... Ongoing Karo Healthcare collaboration/launch is crucial but no info since November. Have been involved for a long time but if no info comes within a couple of months then that's enough.
·1 päivä sittenIt's probably a sound thought for 1-2 more months, after that the year's season is over and it takes 8 months until the next one starts. However, Moberg has Sweden Norway with modest revenues during that time so there is no danger for the company. But we want to move forward asap.....and get information.·1 päivä sitten · MuokattuYes, I agree that it's not a danger for the company. However, I've been invested for a few years and am in pricip break-even (some % down). During the same time, I would have gained 50%+ in e.g. Investor. After the setback in US, it has simply gone too slowly enlig me. So if this year's window with Karo is missed, then I'm out.- ·23.3.Query: we have not yet seen any communication regarding Karo Healthcare and the launch of Terclara under the Lamisil brand... does that mean one misses this year's season? Q1-Q2 are indeed the strongest quarters for this type of product...
·23.3.I understand your concern. But Moberg has not previously shown themselves to be masters of communication. I believe that the focus is on the business more than on the stock, and that is probably perfectly fine in the long run. - 30.3.30.3.Tämä julkaisu on poistettu.
·24.3.Reminds me of when the pandemic was declared. Pretty much everything fell 20%, regardless of industry. 
·20.3.I have used Terclara daily for over 2 years without any brilliant results. I therefore asked CoPilot what experience others have. Answer: "Summary of user feedback Many report no or minimal improvement despite long-term use. Some experience faster cosmetic improvement, but the nail does not become healthy. Several express disappointment that the effect does not match the marketing. Your two years without results are therefore unfortunately not uncommon."·23.3.But Jessel, then sell your holding if you don't believe in the product and put the money into something else....
·23.3.Jessel - but your posts clearly scream that you want to warn everyone that the company's products don't work - but it DOES work - just not for you. So it's very difficult to interpret as anything other than that you also don't think one should own/buy the shares - but we're doing it anyway - because it's a unique product with huge market potential
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
45 päivää sitten
6,2762 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·30.3.The company's communication to shareholders is deplorable. A company in this situation that communicates 1 time per quarter... and not very much even then. And their page on Linkedin (which after all many look up and they have 2000+ followers) where the About section was updated 2022... Ongoing Karo Healthcare collaboration/launch is crucial but no info since November. Have been involved for a long time but if no info comes within a couple of months then that's enough.·1 päivä sittenIt's probably a sound thought for 1-2 more months, after that the year's season is over and it takes 8 months until the next one starts. However, Moberg has Sweden Norway with modest revenues during that time so there is no danger for the company. But we want to move forward asap.....and get information.·1 päivä sitten · MuokattuYes, I agree that it's not a danger for the company. However, I've been invested for a few years and am in pricip break-even (some % down). During the same time, I would have gained 50%+ in e.g. Investor. After the setback in US, it has simply gone too slowly enlig me. So if this year's window with Karo is missed, then I'm out.
- ·23.3.Query: we have not yet seen any communication regarding Karo Healthcare and the launch of Terclara under the Lamisil brand... does that mean one misses this year's season? Q1-Q2 are indeed the strongest quarters for this type of product...·23.3.I understand your concern. But Moberg has not previously shown themselves to be masters of communication. I believe that the focus is on the business more than on the stock, and that is probably perfectly fine in the long run.
- 30.3.30.3.Tämä julkaisu on poistettu.·24.3.Reminds me of when the pandemic was declared. Pretty much everything fell 20%, regardless of industry.
- ·20.3.I have used Terclara daily for over 2 years without any brilliant results. I therefore asked CoPilot what experience others have. Answer: "Summary of user feedback Many report no or minimal improvement despite long-term use. Some experience faster cosmetic improvement, but the nail does not become healthy. Several express disappointment that the effect does not match the marketing. Your two years without results are therefore unfortunately not uncommon."·23.3.But Jessel, then sell your holding if you don't believe in the product and put the money into something else....·23.3.Jessel - but your posts clearly scream that you want to warn everyone that the company's products don't work - but it DOES work - just not for you. So it's very difficult to interpret as anything other than that you also don't think one should own/buy the shares - but we're doing it anyway - because it's a unique product with huge market potential
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 17.2. | ||
2025 Q3 -tulosraportti 11.11.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 13.5.2025 | ||
2024 Q4 -tulosraportti 11.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
45 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 17.2. | ||
2025 Q3 -tulosraportti 11.11.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 13.5.2025 | ||
2024 Q4 -tulosraportti 11.2.2025 |
6,2762 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·30.3.The company's communication to shareholders is deplorable. A company in this situation that communicates 1 time per quarter... and not very much even then. And their page on Linkedin (which after all many look up and they have 2000+ followers) where the About section was updated 2022... Ongoing Karo Healthcare collaboration/launch is crucial but no info since November. Have been involved for a long time but if no info comes within a couple of months then that's enough.·1 päivä sittenIt's probably a sound thought for 1-2 more months, after that the year's season is over and it takes 8 months until the next one starts. However, Moberg has Sweden Norway with modest revenues during that time so there is no danger for the company. But we want to move forward asap.....and get information.·1 päivä sitten · MuokattuYes, I agree that it's not a danger for the company. However, I've been invested for a few years and am in pricip break-even (some % down). During the same time, I would have gained 50%+ in e.g. Investor. After the setback in US, it has simply gone too slowly enlig me. So if this year's window with Karo is missed, then I'm out.
- ·23.3.Query: we have not yet seen any communication regarding Karo Healthcare and the launch of Terclara under the Lamisil brand... does that mean one misses this year's season? Q1-Q2 are indeed the strongest quarters for this type of product...·23.3.I understand your concern. But Moberg has not previously shown themselves to be masters of communication. I believe that the focus is on the business more than on the stock, and that is probably perfectly fine in the long run.
- 30.3.30.3.Tämä julkaisu on poistettu.·24.3.Reminds me of when the pandemic was declared. Pretty much everything fell 20%, regardless of industry.
- ·20.3.I have used Terclara daily for over 2 years without any brilliant results. I therefore asked CoPilot what experience others have. Answer: "Summary of user feedback Many report no or minimal improvement despite long-term use. Some experience faster cosmetic improvement, but the nail does not become healthy. Several express disappointment that the effect does not match the marketing. Your two years without results are therefore unfortunately not uncommon."·23.3.But Jessel, then sell your holding if you don't believe in the product and put the money into something else....·23.3.Jessel - but your posts clearly scream that you want to warn everyone that the company's products don't work - but it DOES work - just not for you. So it's very difficult to interpret as anything other than that you also don't think one should own/buy the shares - but we're doing it anyway - because it's a unique product with huge market potential
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt